Invitrogen, Distended by Big Acquisitions, Will Now Concentrate on Fewer, Smaller Buys | GenomeWeb
NEW YORK (GenomeWeb News) –Invitrogen, distended from a binge of acquisitions in 2004 and 2005, will focus on fewer and smaller buys in the future, a company official said this week.
 
Speaking at the Lehman Brothers Global Healthcare Conference in Miami, CFO David Hoffmeister said the firm will most likely make tuck-in acquisitions this year, though it does not see gaps in its portfolio.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.